Ipamorelin built its reputation on selectivity: a growth-hormone pulse without the cortisol, prolactin, and appetite chaos of earlier GHRPs. That's real pharmacology - Novo Nordisk developed it seriously enough to run human trials before abandoning it. What clinics built on top of that foundation is a different story, and the FDA's Category 2 designation was aimed at exactly that gap.
What ipamorelin is
Ipamorelin is a pentapeptide ghrelin-receptor agonist (a GHRP) that triggers pituitary growth-hormone release. Its distinction in the class is selectivity: in the original pharmacology, it stimulated GH with minimal effect on cortisol, prolactin, and ACTH - the side-channels that made GHRP-2 and GHRP-6 messy. It also has a genuine pharmaceutical past: Novo Nordisk trialed it (as NN703-adjacent work and for post-operative ileus) before discontinuing development in the 2000s.
The evidence: hormone yes, outcomes no
- Confirmed: acute GH release in human pharmacology studies - the mechanism is not in dispute.
- Absent: any controlled human trial showing muscle gain, fat loss, better sleep, or 'anti-aging' outcomes from ipamorelin use in healthy adults.
- The abandoned development program matters: a major pharma held this molecule and did not find a path worth funding to approval.
Every clinic menu bridging that gap ('GH optimizes body composition, therefore ipamorelin does') is selling a syllogism, not a study.
Why the FDA singled it out
When the FDA sorted compounding nominations, ipamorelin landed in Category 2 - substances with significant safety risks - citing the unknowns (immunogenicity, long-term endocrine effects) that an abandoned development program never resolved. Practically, that ended the legal compounding lane that anti-aging clinics had used, which is why post-2023 menus quietly swapped toward sermorelin (which has an approval history) or dropped the category.
The dosage math
Gray-market discussion clusters around 200-300 mcg one to three times daily - extrapolated from pharmacology studies, not outcome trials. From a 5 mg vial with 2 ml of bacteriostatic water (2.5 mg/ml), 300 mcg is 0.12 ml = 12 units. The ipamorelin calculator converts your numbers and flags misreads; blends with CJC-1295 need the blend page because vial labeling differs.
Side effects and unknowns
Short-term pharmacology reported flushing, headache, and injection-site reactions; as a ghrelin agonist it can nudge hunger despite its reputation as the 'appetite-neutral' GHRP. The consequential unknowns are chronic: what years of induced GH pulses do to glucose handling, tissue growth, and endocrine feedback in healthy adults has never been studied - and pharma declining to find out is itself information.
Frequently asked questions
What does ipamorelin do?
It triggers pituitary growth-hormone release via the ghrelin receptor, with unusual selectivity (minimal cortisol/prolactin effect). That hormone-level effect is documented; downstream benefits - muscle, fat loss, sleep, longevity - have no controlled human evidence.
Is ipamorelin legal?
It sits in FDA Category 2, which blocks legal compounding, and no approved product exists - so selling it for human use is unlawful. Possession isn't prosecuted. In sport it's prohibited at all times (WADA S2).
Ipamorelin vs sermorelin - what's the practical difference?
Different receptors (ghrelin vs GHRH), same unproven outcome layer. The practical 2026 difference is regulatory: sermorelin's approval history (Geref) preserves a defensible compounding lane; ipamorelin's Category 2 status closed its own.
How long does ipamorelin take to work?
The GH pulse is immediate (minutes, in pharmacology studies). For the marketed benefits there is no evidence-based timeline, because no controlled outcome has been demonstrated at any timepoint.